South San Francisco-based Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of patients with cancer. Founded in 2015 by Luke Evnin and Patrick Baeuerle, Harpoon Therapeutics is backed by investors that include Arix Bioscience, MPM Capital, New Leaf Venture Partners, OrbiMed, and UBS Asset Management.